Pacing to Maintain Physiologic Ventricular Activation (Pace-Conduct)

Pacing for Cardiac Resynchronisation Using the Intrinsic Conduction System to Maintain Physiologic Ventricular Activation

Right ventricular pacing causes ventricular dyssynchrony and may be associated with impaired outcome. In the last decade, several approaches for more physiological pacing became available and were implemented in the latest guidelines. However, compared to conventional device implantation, cardiac resynchronization, His bundle pacing and left bundle area pacing remain demanding procedures in the individual case. Goal of the single center observational "Pace conduct" study is to evaluate implantation success, safety and outcome of pacing methods that maintain physiologic ventricular activation.

Study Overview

• Status: Recruiting
• Conditions: Left Bundle-Branch Block; Pacemaker DDD; Pacing-Induced Cardiomyopathy; ICD; His Bundle Pacing; LBB Area Pacing
• Intervention / Treatment: Device: cardiac implantable electronic device (CIED) implantation

Detailed Description

Background:

Conventional ectopic myocardial right ventricular pacing (RVP) causes ventricular dyssynchrony and may be associated with reverse ventricular remodeling, reduced ejection fraction (EF), left ventricular dilatation, functional mitral valve regurgitation, heart failure and an increased rate of new onset atrial fibrillation.

Dependent on individual patient's characteristics, several strategies are established to prevent and to overcome the potential drawbacks of chronic RVP. In general, unnecessary ectopic RVP should be avoided. For example, in patients with sinus node disease and intact atrioventricular (AV) conduction, atrial pacing, AV (search) hysteresis or AAI-DDD/ADI pacing may be used. In patients with impaired cardiac function and an expected higher percentage of RVP, pacing strategies for cardiac resynchronization are indicated. Conventional cardiac resynchronization therapy (CRT) uses an additional transvenous left ventricular lead for synchronous ventricular stimulation and was shown to shorten QRS duration and to reduce morbidity and mortality in patients with chronic heart failure, left bundle branch block (LBBB) and reduced EF. Due to the non-physiological left ventricular epicardial stimulation, however, conventional CRT is associated with 30% of non-responders and may even prolong ventricular activation in patients with narrower QRS complex. First described in 1968, His bundle pacing (HBP) has evolved to an increasingly used alternative for cardiac pacing. Currently, HBP is regarded the most physiologic approach for ventricular stimulation because it prevents ventricular dyssynchrony and its potential fatal long-term consequences by preserving normal electrical activation of the ventricles. Clinical benefit of HBP has been shown compared with conventional permanent RVP and CRT. Recent studies documented restoration of normal electrical and mechanical left ventricular synchrony for both selective and non-selective HBP. However, compared with conventional RVP the implantation procedure for HBP is much more demanding requiring exact placement of the pacing lead within the anatomically variable His bundle area. Alternatively, the correction of bundle branch conduction disorders has been demonstrated for left bundle branch area (LBBA) pacing. As a consequence, current guidelines recommend pacing methods that maintain physiologic ventricular activation in patients with atrioventricular block who have an indication for permanent pacing with a LVEF between 36% and 50% and are expected to require ventricular pacing more than 40% of the time (class IIa indication).

In summary, there is increasing evidence showing the benefits of the different strategies for physiologic pacing but the appropriate use of these approaches may be challenging in the individual case. Therefore, appropriate patient selection, implantation approaches, device programming and follow-up require further intensive evaluation.

Objective:

Main goal of the study is to evaluate implantation success for pacing methods aiming to maintain physiologic ventricular activation. Procedural success is defined as stable lead positioning and effective pacing within the target area with an appropriate and stable pacing threshold.

Secondary goals of the study are to document and to evaluate

• procedural parameters (e.g. venous access, time needed for lead implant, procedural duration, radiation) and adverse events dependent on procedural approaches and patients characteristics,
• performance of the implanted system (sensing, pacing thresholds) and clinical outcome during routine follow-up

Study design:

Single center, non-randomized, observational study, retrospective data analysis, on-going prospective patient enrollment, descriptive statistics.

Center: Klinikum Fuerth (Dept. for Heart and Lung diseases, section for clinical electrophysiology) / Germany in cooperation with the Dept. of Cardiology of the University Erlangen / Germany and the University of Trieste / Italy.

Patients and methods:

Primary endpoint: Implantation success. Effective pacing and acceptable pacing threshold at the targeted lead position. Target for lead placement is the area with maximum delayed ventricular activation for transvenous CRT, the His bundle for selective or non-selective HBP and the right interventricular septum with left bundle branch capture for LBBA pacing, respectively. Target thresholds for the lead placed within the coronary sinus or at the intrinsic conduction system is <2.5 V @ 1 ms with a maximum acceptable threshold of <4.0 V @ 2 ms or <5 V @ 1 ms. Target for all other leads is <1 V @ 0.5 ms.

Secondary endpoints: patient characteristics and association with outcome. Implantation success and outcome correlated with patient characteristics including electrocardiogram and echocardiographic parameter and procedure related techniques and parameter. Safety: radiation exposure, number and type of adverse events and adverse device related events. Follow-up: device function, interrogation, programming and clinical outcome as evaluated in routine follow-up, incl. ECG, echocardiography and parameter for assessment of heart failure. Subpopulations: managed ventricular pacing, His bundle pacing, LBB-area pacing, CRT. Implantation with or without electroanatomic mapping system.

Inclusion criteria:

Implantation of a pacemaker or ICD according to the current guidelines (Class I or IIa indication) aiming to avoid pacing induced dyssynchrony, e.g. managed ventricular pacing, His-bundle pacing, LBB-area pacing or conventional transvenous CRT. Age ≥ 18 years.

Exclusion criteria:

No given informed consent for the procedure. No follow up data available.

Sample size:

For the observational study, there is no pre-specified sample-size. Data from 200 patients and procedures are expected.

Data security:

Study related data are collected by the study investigators in an anonymous clinic-internal data-base that is password protected. All investigators have to provide valid GCP training.

Risk estimation:

The study is observational and descriptive with anonymized data collection and data analysis. Therefore, the study adds no risk to the study population.

Ethics:

The "Pace-Conduct" study has been approved by the responsible ethics committee of the Friedrich- Alexander University Erlangen, Germany (145_20 Bc)

• Study Type: Observational
• Enrollment (Estimated): 200

Contacts and Locations

• Study Contact: Name: Dirk Bastian, MD; Phone Number: +49 911 7580 1101; Email: dirk.bastian@klinikum-fuerth.de
• Study Contact Backup: Name: Laura Vitali-Serdoz, MD; Phone Number: +49 911 7580 1101; Email: laura.vitali-serdoz@klinikum-fuerth.de

Study Locations

• Germany
  • Bavaria
    • Fuerth, Bavaria, Germany, 90766
      • Recruiting
      • Klinikum Fuerth
      • Contact: Dirk Bastian, MD; Phone Number: +49 (0)911 7580 1101; Email: dirk.bastian@klinikum-fuerth.de
      • Contact: Laura Vitali-Serdoz, MD; Phone Number: +49 (0)911 7580 1101; Email: laura.vitali-serdoz@klinikum-fuerth.de

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 16 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No

• Sampling Method: Non-Probability Sample

Study Population

Patients undergoing Pacemaker or ICD Implantation according to current Guidelines with the aim to avoid pacing induced ventricular dyssynchrony.

Subgroups according to type of device implanted, lead Position and programming.

Description

Inclusion Criteria:

• Pacemaker or ICD Implantation aiming to avoid pacing induced ventricular dyssynchrony according to current guidelines
• age >= 18 years

Exclusion Criteria:

• no informed consent for the procedure given
• no follow-up data

Study Plan

How is the study designed?

Design Details

• Observational Models: Cohort
• Time Perspectives: Prospective

Number of groups / cohorts

1

Cohorts and Interventions

Group / Cohort	Intervention / Treatment
CIED for cardiac resynchronisation; Patients implanted with an CIED for cardiac resynchronisation aiming to avoid pacing induced ventricular dyssynchrony, e.g. His bundle pacing, LBB-area pacing, CRT. These different implanted types of devices may be further analysed as subgroups.	Device: cardiac implantable electronic device (CIED) implantation; CIED Implantation according to the Guidelines aiming to avoid pacing induced dyssynchrony

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
CIED Implantation success	successful Pacemaker- or ICD implantation with effective pacing and acceptable pacing threshold in the targeted area	peri-procedural

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
pre-operative: Implantation related Patient characteristics	association with procedural and post-implant outcome	1 month post implantation
intra-procedural: implant success related with procedural characteristics	correlation of Implantation success with Patient characteristics and procedural technical Parameter, eg. use of an electroanatomic mapping system	peri-procedural
peri-procedural: safety and radiation	Radiation exposure and number and type of all adverse Events and adverse device associated events	peri-procedural
follow-up: device function	device parameter and programming during follow up	one year
follow-up: outcome	clinical Outcome during follow up	one year

Collaborators and Investigators

• Sponsor: Klinikum-Fuerth
• Collaborators: University of Erlangen-Nürnberg; University of Trieste
• Investigators: Principal Investigator: Dirk Bastian, MD, Klinikum-Fuerth

Publications and helpful links

General Publications

• Bastian D, Gregorio C, Buia V, Walaschek J, Rittger H, Vitali-Serdoz L. His bundle pacing guided by automated intrinsic morphology matching is feasible in patients with narrow QRS complexes. Sci Rep. 2022 Mar 4;12(1):3606. doi: 10.1038/s41598-022-07516-6.

Study record dates

Study Major Dates

• Study Start (Actual): January 1, 2018
• Primary Completion (Estimated): December 1, 2025
• Study Completion (Estimated): December 1, 2030

Study Registration Dates

• First Submitted: June 1, 2020
• First Submitted That Met QC Criteria: June 1, 2020
• First Posted (Actual): June 4, 2020

Study Record Updates

• Last Update Posted (Actual): July 6, 2023
• Last Update Submitted That Met QC Criteria: July 5, 2023
• Last Verified: June 1, 2023

More Information

Terms related to this study

• Keywords: cardiac resynchronisation therapy; His bundle pacing; LBB area pacing
• Additional Relevant MeSH Terms: Pathologic Processes; Heart Diseases; Cardiovascular Diseases; Arrhythmias, Cardiac; Cardiac Conduction System Disease; Heart Block; Bundle-Branch Block; Cardiomyopathies
• Other Study ID Numbers: Pace_Cond_KHF

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No